Abstract
There are two sides to the discussion of phenotypes in vascular aging. One is to acknowledge that different biological phenotypes have a clear interaction with vascular aging and are responsible for modulating its progression or for mediating the effect of different risk factors in its progression. The other is to comprehend that chronobiologic asynchrony determines phenotypes of vascular aging that carry different risks of vascular disease and may potentially be of use in clinical practice in primary or secondary prevention strategies and precision medicine decisions. It should be clear that the authors are not pushing the agenda that pulse wave velocity (PWV) should be used as a treatment target yet. The goal is to underline evidence-based clinical situations when it is useful to use PWV or phenotypes that either associate with it or include it as one of the distinctive features. Finally, by acknowledging (with progressively robust evidence) that several biomarkers of hemodynamic function and structure related to vascular aging carry distinct information on cardiovascular risk, new research areas in the field are open, and new phenotypes with potential clinical importance can be unveiled.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
